Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Change in Cash (2023 - 2025)

Historic Change in Cash for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to -$42.0 million.

  • Genmab A's Change in Cash rose 9526.49% to -$42.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $332.0 million, marking a year-over-year increase of 11527.84%. This contributed to the annual value of $332.0 million for FY2025, which is 13742.95% up from last year.
  • Latest data reveals that Genmab A reported Change in Cash of -$42.0 million as of Q4 2025, which was up 9526.49% from $461.0 million recorded in Q3 2025.
  • In the past 5 years, Genmab A's Change in Cash ranged from a high of $461.0 million in Q3 2025 and a low of -$3.5 billion during Q4 2023
  • Moreover, its 3-year median value for Change in Cash was -$76.0 million (2024), whereas its average is -$592.0 million.
  • Data for Genmab A's Change in Cash shows a peak YoY increase of 40394.74% (in 2025) and a maximum YoY decrease of 6405.69% (in 2025) over the last 5 years.
  • Over the past 3 years, Genmab A's Change in Cash (Quarter) stood at -$3.5 billion in 2023, then surged by 74.56% to -$887.0 million in 2024, then surged by 95.26% to -$42.0 million in 2025.
  • Its Change in Cash was -$42.0 million in Q4 2025, compared to $461.0 million in Q3 2025 and -$318.0 million in Q2 2025.